Anti-hepatitis B virus activity and metabolism of 2',3'dideoxy-2',3'- didehydro-β-L(-)-5-fluorocytidine

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1805-1810

  Zhu, Yong Lian ^a,b   Dutschman, Ginger E ^a   Liu, Shwu Huey ^a   Bridges, Edward G ^a   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 2',3' DIDEOXYCYTIDINE; FLUCYTOSINE DEOXYRIBOSIDE; LAMIVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; HEPATITIS B; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0031808360     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1805     Document Type: Article

References (19)

1. Beasley, R. P., L. Y. Hwang, C. C. Lin, and S. Chien. 1981. Hepatocellular carcinoma and hepatitis B virus. Lancet ii:1124-1133.
2. Benhamou, Y., E. Dohin, F. Lunel-Fabiani, T. Poynard, J. M. Huraus, C. Katlama, P. Opolon, and M. Gentilini. 1994. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345:396-397.
3. Centers for Disease Control and Prevention. 1995 Cases of selected notifiable diseases. Morbid. Mortal. Weekly Rep. 1995:43-963.
4. Chang, C.-N., S.-L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C. H. Tsai, D. C. Liotta, R. F. Schinazi, and Y.-C. Cheng. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2±,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
5. Cheng, Y.-C., B. Domin, and L.-S. Lee. 1977. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim. Biophys. Acta 481:481-492.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108.
7. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
8. Doong, S. I., C. H. Tsai, R. F. Schinazi, D. C. Liotta, and Y. C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiapyrimidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
9. Dutschman, G. E., E. G. Bridges, S.-H. Liu, E. Gullen, X. Guo, M. Kukhanova, and Y.-C. Cheng. 1998. Metabolism of 2′,3′-dideoxy-2′,3′-dehydro-β-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42:1799-1804.
10. Faraj, A., R. F. Schinazi, A. Joudawlkis, Z. Lesnikowski, A. McMillan, C. D. Morrow, and J.-P. Sommadossi. 1997. Effects of β-D-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine 5′-triphosphate (β-D-D4FC-TP) and its β-L-enantiomer 5′-triphosphate (β-L-D4FC-TP) on viral DNA polymerases. Antivir. Res. 34:A66.
11. Fischer, K. P., and D. L. J. Tyrrell. 1996. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-L-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob. Agents Chemother. 40:1957-1960.
12. Furman, P. A., M. Davis, D. C. Liotta, M. Paff, L. W. Frick, D. J. Nelson, R. E. Dornsife, J. A. Wurster, L. J. Wilson, J. A. Fyfe, J. V. Tuttle, W. H. Miller, L. Condreay, D. R. Averett, R. F. Schinazi, and G. R. Painter. 1992. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob. Agents Chemother. 36:2686-2692.
13. Honkoop, P., H. G. M. Niesters, R. A. M. Deman, A. D. M. E. Osterhaus, and S. W. Schalm. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26:1393-1395.
14. Kukhanova, M., and Y.-C. Cheng. 1997. Unpublished data.
15. Lin, T.-S., M.-Z. Luo, M.-C. Liu, Y.-L. Zhu, E. Gullen, G. E. Dutschman, and Y.-C. Cheng. 1996. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C). two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1757-1759.
16. Ling, R., D. Mutimer, M. Ahmed, E. H. Boxall, E. Elias, G. M. Dusheiko, and T. J. Harrison. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713.
17. Severini, A., X.-Y. Liu, J. S. Wilson, and D. L. J. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
18. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. Tyrrell. 1996. Mutation in HBV RNA-dependent polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
19. Tyrrell, D. L. J., M. C. Mitchell, R. DeMon, S. W. Schalm, J. Main, H. C. Thomas, J. Fevery, F. Nevens, P. Beranck, and C. Vicary. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A.